Finoriq research workspace
Aurinia Pharmaceuticals Inc. (AUPH) Historical Metrics
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people. Review AUPH fundamentals, ratios, and historical filing metrics on Finoriq.
Company Snapshot
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
- Company
- Aurinia Pharmaceuticals Inc. (AUPH)
- Ticker
- AUPH
- Market Cap
- $2B
- Latest Price
- $15.36
- Industry
- Biotech & Pharma
Aurinia Pharmaceuticals Inc. (AUPH) Current Valuation Metrics
Static valuation preview for Aurinia Pharmaceuticals Inc. (AUPH). Market data retrieved 2026-07-08. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/EMarket cap divided by latest TTM net income. | 7.03x | Net Income | TTM Q1 2026 |
| P/SMarket cap divided by latest TTM revenue. | 7.03x | Revenue | TTM Q1 2026 |
| P/Operating Cash FlowMarket cap divided by latest TTM operating cash flow. | 12.6x | Operating Cash Flow | TTM Q1 2026 |
| Earnings YieldLatest TTM net income divided by market cap. | 14.2% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | 8.0% | Operating Cash Flow | TTM Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.